Timely genomic testing for lung cancer – EGFR Positive UK

EGFR Positive UK shared on X:

“EGFR and ROS-1 co-occurrence in lung cancer may be more common than thought.

Patients must have access to timely genomic testing for effective treatment paths. 40% of our community faced delays in mutation ID and only 40% were offered rebiopsy on progression.

Comment: EGFR+ patient data is from our 2024 Members’ Survey – the largest survey of UK EGFR patients. Sign up for early access and get the full survey report on Monday 8th July.”

Read further.
Source: EGFR Positive UK/X